MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2023 07:30 ET
|
MiNK Therapeutics
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of...
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
May 22, 2023 08:30 ET
|
MiNK Therapeutics
75% survival in patients with severe respiratory distress treated with agenT-797agenT-797 improved lung function, significantly reduced inflammation and secondary infectionsMiNK to advance agenT-797...
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
May 18, 2023 08:30 ET
|
MiNK Therapeutics
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC modelsIND enabling studies underway; IND filing on track for 2024 ...
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
May 11, 2023 08:00 ET
|
MiNK Therapeutics
agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists without lymphodepletion.Initiating phase 1/2...
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
April 27, 2023 08:30 ET
|
MiNK Therapeutics
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
April 18, 2023 13:32 ET
|
MiNK Therapeutics
Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.In a patient with metastatic gastric cancer who...
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 21, 2023 08:00 ET
|
MiNK Therapeutics
Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in...
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
March 15, 2023 08:45 ET
|
MiNK Therapeutics
– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc....
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
March 07, 2023 09:00 ET
|
MiNK Therapeutics
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference
February 16, 2023 09:28 ET
|
MiNK Therapeutics
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...